RxDoctor Payments Data

Sarah Nowicki-Duczeminski, OD

Optometrist · Wilmington, DENPI 1861844466

Payments from drug & device makers

What this record shows

13 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 55.0% of the total. Reporting peaked in 2019 at $1,698 and has fallen 84.9% since, to $256 in 2025. Among optometrist clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,731in general payments, 2019–2025

Across 62 payments — averaging $44.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • AbbVie$211
  • Alcon$186
  • Johnson & Johnson Vision Care, Inc.$185
  • Tarsus Pharmaceuticals, Inc.$175
  • Kala Pharmaceuticals, Inc.$134
  • plus $336 from 7 others

What the payments were for

  • Travel & lodging$1,20144%
  • Food & beverage$1,52956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,731 in reported general payments places this provider in the 90th percentile of 146 optometrist providers in Delaware.

See all optometrist providers in Delaware

Medicare billing

Part B allowed, 2024
$113,339
Medicare patients
831
Services billed
1,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$52,455
SimbrinzaBrinzolamide/Brimonidine Tart14$3,497
Latanoprost142$2,779
Prednisolone Acetate28$1,722
Brimonidine Tartrate27$1,092
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$826
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha55$544
Timolol Maleate37$416
Dorzolamide Hcl20$262
Minocycline Hcl20$229
Ofloxacin16$153
ErythromycinErythromycin Base16$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$211$52,45545 claims
AlconSimbrinza$186$3,49714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 146 optometrist providers in Delaware.

Other optometrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →